Axsome Therapeutics (AXSM) Amortization of Deferred Charges (2015 - 2017)

Axsome Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at $314000.0 in Q1 2023.

• Quarterly Amortization of Deferred Charges rose 14.18% year-over-year to $314000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $1.2 million (up 9.98% YoY) and the FY2022 annual result came in at $1.2 million, up 7.62% from the prior year.
• Amortization of Deferred Charges retreated to $314000.0 in Q1 2023 per AXSM's latest filing, from $324531.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $324531.0 in Q4 2022 and troughed at $262764.0 in Q1 2021.
• A 3-year average of $283868.7 and a median of $276364.0 in 2021 frame the typical range for Amortization of Deferred Charges.
• The widest YoY moves for Amortization of Deferred Charges: up 17.43% in 2022, down 3.85% in 2022.
• Over 3 years, Amortization of Deferred Charges stood at $276364.0 in 2021, then advanced by 17.43% to $324531.0 in 2022, then declined by 3.24% to $314000.0 in 2023.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $314000.0, $324531.0, and $283014.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.